var data={"title":"Pirfenidone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pirfenidone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/537130?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pirfenidone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pirfenidone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26312832\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Esbriet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237709\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Esbriet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243603\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-inflammatory Agent;</li>\n      <li>\n        Antifibrotic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243553\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Idiopathic pulmonary fibrosis (IPF):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Days 1 to 7: 267 mg 3 times daily (total dose: 801 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Days 8 to 14: 534 mg 3 times daily (total dose: 1,602 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Day 15 and thereafter: 801 mg 3 times daily (total dose: 2,403 mg/day). Maximum dose: 2,403 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Reinitiation of therapy following interruption:</i> If interruption &lt;14 consecutive days, may reinitiate therapy at previous daily dose without retitration; if interruption &ge;14 consecutive days, reinitiate therapy with the initial 2-week titration period up to recommended daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Strong CYP1A2 inhibitors (eg, fluvoxamine): Reduce pirfenidone to 267 mg 3 times daily (total dose: 801 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate CYP1A2 inhibitors (eg, ciprofloxacin): Reduce pirfenidone to 534 mg 3 times daily (total dose: 1,602 mg/day) when used concomitantly with ciprofloxacin 1,500 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237909\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243554\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution; consider dose modification or discontinuation as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD requiring dialysis: Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243555\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A and B): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution; consider dose modification or discontinuation as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243556\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Gastrointestinal (eg, nausea, diarrhea, dyspepsia, vomiting):</i> There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, consider temporary dosage reduction and/or therapy interruption to allow for resolution of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ALT/AST &gt;3 to &le;5 x ULN (without hyperbilirubinemia): Rule out alternative causes and discontinue potentially confounding medications. As clinically appropriate, may continue current dose, may reduce dose (specific dosing reductions are not provided in manufacturer&rsquo;s labeling), or may temporarily discontinue therapy. Once aminotransferase elevations have resolved, may be re-titrated to the recommended daily dose. Monitor LFTs closely thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ALT/AST &gt;3 to &le;5 x ULN with hyperbilirubinemia or symptoms: Discontinue therapy promptly and do not reinitiate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ALT/AST &gt;5 x ULN (regardless of serum bilirubin concentrations): Discontinue therapy promptly and do not reinitiate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Photosensitivity reaction or rash:</i> There is no specific dosage adjustment provided in the manufacturer&rsquo;s labeling; however, consider temporary dosage reduction and/or therapy interruption to allow for resolution of symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26312833\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Esbriet: 267 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Esbriet: 267 mg, 801 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26312831\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243562\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esbriet: 267 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esbriet: 267 mg (63s) [2-week Initiation Pack]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esbriet: 267 mg (252s) [4-week Maintenance Pack]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243557\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food at the same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237770\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Idiopathic pulmonary fibrosis:</b> Treatment of idiopathic pulmonary fibrosis (IPF)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237800\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (22% to 26%), headache (10% to 22%), dizziness (9% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (29% to 30%; Japanese patients: 9%), skin photosensitivity (9% to 12%; Japanese patients: 51%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (33% to 36%), diarrhea (22% to 26%), abdominal pain (5% to 24%), dyspepsia (17% to 19%), anorexia (9% to 13%), vomiting (9% to 13%), gastroesophageal reflux disease (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (3% to 27%), sinusitis (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;3% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (4% to 10%), noncardiac chest pain (1% to 5%), drowsiness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (4% to 8%), macular eruption (4%), sunburn (4%), erythema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (6% to 10%), increased gamma-glutamyl transferase (5%), hot flash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distension (9%), decreased appetite (8%), abdominal distress (3% to 8%), dysgeusia (1% to 6%), flatulence (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (4%), increased serum transaminases (ALT and AST; &ge;3 x ULN: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1% to 10%), weakness (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;1% to &lt;3%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Lethargy, malaise, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Desquamation, erythematous rash, hyperhidrosis, maculopapular rash, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dyslipidemia, fluid retention, gout, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypoglycemia, hypokalemia, hyponatremia, increased lactate dehydrogenase, vitamin D deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Frequent bowel movements, gastritis, increased appetite</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection, vaginal infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, myalgia, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, throat irritation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anemia, angioedema, atrial fibrillation, atrioventricular block (first and second degree), bradycardia, candidiasis, cholecystitis, decreased hemoglobin, decreased platelet count, dehydration, esophagitis, febrile neutropenia, flushing, hepatitis, herpes zoster, hyperbilirubinemia, hyperkalemia, increased blood urea nitrogen, increased C-reactive protein, increased troponin, intestinal obstruction, leukopenia, neutropenia, palpitations, pneumonia, pneumonitis, pneumothorax, prolonged QT-interval on ECG, pulmonary aspergillosis, renal insufficiency, respiratory failure, supraventricular tachycardia, ulcer with hemorrhage (gastric), ventricular tachycardia, viral respiratory tract infection, xanthoderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237774\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to pirfenidone or any component of the formulation; history of angioedema with pirfenidone; concomitant use of fluvoxamine; severe hepatic impairment or end-stage liver disease; severe renal impairment (CrCl &lt;30 mL/minute) or end-stage renal disease (ESRD) requiring dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237775\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness and/or fatigue which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Incidence of dizziness may be reduced by administering with food. Dose reduction or discontinuation may be necessary if symptoms fail to improve or worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Adverse effects including nausea/vomiting, diarrhea, dyspepsia, gastroesophageal reflux disease, and abdominal pain have been reported; incidence may be reduced by administering with food. The incidence of gastrointestinal events was highest early in the course of treatment (initial 3 months) and decreased over time. Consider dose reduction or discontinuation of therapy if lack of improvement or worsening of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increased transaminases (ALT/AST) and hyperbilirubinemia have been reported with use; evaluate liver function prior to therapy initiation and during therapy. Dose reduction or discontinuation of therapy may be necessary. Discontinue therapy immediately for transaminases &gt;5 x ULN or for increased transaminases that are accompanied by symptoms (eg, jaundice) or hyperbilirubinemia; monitor closely and do not rechallenge with pirfenidone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Photosensitivity reactions and rash have been reported with the majority of reactions occurring during the initial 6 months of therapy (severe reactions are uncommon); instruct patients to avoid or minimize exposure to the sun and/or sun lamps, to apply sunscreen (SPF &ge;50 against UVA and UVB), wear protective clothing/hats, and to avoid concurrent use of other photosensitizing drugs. Patients should promptly report symptoms, reaction, or rash; dose reduction or therapy interruption may be necessary. If appropriate, may reinitiate therapy with re-escalation of dose as tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight loss: Weight loss/anorexia have been reported with use; monitor weight during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in mild to moderate impairment (Child-Pugh class A and B); pirfenidone systemic exposure increased by 60% in moderate impairment. Use in severe impairment (Child-Pugh class C) is not recommended (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; consider dose reduction and/or discontinuation as necessary; use in patients with end stage renal disease requiring dialysis is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cigarette smokers: Clearance may be increased and systemic exposure decreased in cigarette smokers due to hepatic enzyme (ie, CYP1A2) induction. Patients should be instructed to quit smoking prior to initiation of therapy; cigarette smoking should be avoided during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16162284\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16162282\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88424&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Pirfenidone. Management: With ciprofloxacin doses of 1,500 mg/day, the pirfenidone dose should be reduced to 1,602 mg daily (ie, 534 mg three times a day). With lower daily doses of ciprofloxacin, use pirfenidone with caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Pirfenidone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Pirfenidone. Management: Use any such combination with caution and close monitoring for pirfenidone toxicity. Avoid the use of pirfenidone with moderate CYP1A2 inhibitors whenever CYP2C9, 2C19, 2C6, or 2E1 is also inhibited (either by the CYP1A2 inhibitor or by a third drug).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Pirfenidone. Management: See full monograph for specific recommendations.  Canadian product labeling specifically lists the use of pirfenidone with fluvoxamine as contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Pirfenidone. Management: Consider advising patients to limit or avoid grapefruit juice consumption during treatment with pirfenidone.  Canadian product labeling states that grapefruit juice should be avoided during pirfenidone treatment.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Pirfenidone may decrease the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237870\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Food decreased C<sub>max </sub> ~50% and AUC by ~15% to 20% compared to the fasted state. However, incidence of certain adverse events (eg, nausea, dizziness) was decreased when administered with food. Grapefruit products may inhibit the CYP-mediated metabolism of pirfenidone and increase its exposure. Management: Administer with food. Avoid grapefruit products during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237771\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237773\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pirfenidone is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237873\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with food to decrease frequency of dizziness or nausea. Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16243559\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic function (prior to initiation, monthly for first 6 months, then every 3 months); signs of photosensitivity; gastrointestinal events (eg, diarrhea, nausea, vomiting); weight loss </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237874\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Precise mechanisms of action have not been fully elucidated; however, pirfenidone may exert antifibrotic properties by decreasing fibroblast proliferation and the production of fibrosis-associated proteins and cytokines; may decrease the formation and accumulation of extracellular matrix (ie, collagen) in response to transforming growth factor-beta and platelet derived growth factor. Pirfenidone is also believed to exert anti-inflammatory properties by decreasing the accumulation of inflammatory cells resulting from a variety of stimuli. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16237876\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~59 to 71 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Mean: 58% (primarily to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic primarily via CYP1A2 and to a lesser extent via CYP2C9, 2C19, 2D6, and 2E1; major metabolite (5-carboxy-pirfenidone) is inactive</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Median: 0.5 hours (fasting); 3 hours (with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~80%; &gt;99% as metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26597080\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Esbriet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">267 mg (270): $10,221.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Esbriet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">267 mg (90): $3,407.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">801 mg (90): $10,221.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059520\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Esbriet (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, QA, SE, SG, SI, SK, TR);</li>\n      <li>Fibridoner (AR);</li>\n      <li>Kitoscell (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Kitoscell LP (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Pirespa (JP, KR);</li>\n      <li>Pirfenex (IN);</li>\n      <li>Pirfetab (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noble PW, Albera C, Bradford WZ, et al, &ldquo;Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (CAPACITY): Two Randomized Trials,&rdquo; <i>Lancet</i>, 2011, 377(9779):1760-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pirfenidone-drug-information/abstract-text/21571362/pubmed\" target=\"_blank\" id=\"21571362\">21571362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Selman M, King TE, and Pardo A, &ldquo;Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses About Its Pathogenesis and Implications for Therapy,&rdquo; <i>Ann Intern Med,</i> 2001, 134(2):136-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pirfenidone-drug-information/abstract-text/11177318/pubmed\" target=\"_blank\" id=\"11177318\">11177318</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88424 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26312832\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16237709\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16243603\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16243553\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16237909\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16243554\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16243555\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F16243556\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26312833\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26312831\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F16243562\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16243557\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16237770\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16237800\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16237774\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16237775\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16162284\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16162282\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F16237870\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16237771\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16237773\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F16237873\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16243559\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16237874\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F16237876\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26597080\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059520\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88424|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pirfenidone-patient-drug-information\" class=\"drug drug_patient\">Pirfenidone: Patient drug information</a></li></ul></div></div>","javascript":null}